Curated News
By: NewsRamp Editorial Staff
March 24, 2026
Soligenix to Present HyBryte™ CTCL Trial Data at Dermatology Conference
TLDR
- Soligenix's HyBryte shows positive trial data versus Valchlor, potentially offering a competitive therapeutic advantage for cutaneous T-cell lymphoma treatment.
- HyBryte is a novel photodynamic therapy using synthetic hypericin and visible light, with supportive data from long-term studies and comparative analyses presented at medical workshops.
- This development addresses unmet medical needs for rare diseases like CTCL, potentially improving patient outcomes and quality of life through new treatment options.
- Soligenix's late-stage biopharmaceutical work spans from CTCL treatments to vaccine platforms targeting diseases like COVID-19 and Marburg virus.
Impact - Why it Matters
This news matters because cutaneous T-cell lymphoma is a rare and often difficult-to-treat cancer that affects thousands of patients worldwide who have limited treatment options. The presentation of new supportive trial data for HyBryte™ at major dermatology conferences indicates potential progress toward regulatory approval and commercialization of a novel photodynamic therapy that could offer patients a new treatment alternative with potentially fewer side effects than existing options. For investors, this represents a significant milestone for Soligenix as it advances its lead product candidate toward potential market entry, while for the medical community, it signals emerging data that could influence treatment protocols for this challenging condition. The comparative analysis versus Valchlor® is particularly noteworthy as it provides direct evidence of HyBryte™'s relative efficacy and safety profile against an established treatment.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, announced that new supportive trial data for its HyBryte™ (SGX301) treatment for cutaneous T-cell lymphoma (CTCL) will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026, ahead of the American Academy of Dermatology Annual Meeting. The presentations will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor®, supporting HyBryte™'s potential as a therapeutic option for this rare cancer. This development is significant as Soligenix focuses on addressing unmet medical needs in rare diseases, with HyBryte™ representing a novel photodynamic therapy utilizing safe visible light.
The company's Specialized BioTherapeutics business segment is advancing HyBryte™ toward potential commercialization worldwide following successful Phase 3 studies, while also expanding synthetic hypericin into psoriasis treatment and developing first-in-class innate defense regulator technology for inflammatory diseases. Additionally, Soligenix's Public Health Solutions business segment includes vaccine programs for ricin toxin, filoviruses like Marburg and Ebola, and CiVax™ for COVID-19 prevention, supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases. For more details, readers can view the full press release at https://ibn.fm/iTepg or visit the company's newsroom at https://ibn.fm/SNGX for the latest updates relating to SNGX.
Soligenix's announcement comes as the biopharmaceutical industry continues to seek innovative treatments for rare diseases, with the company leveraging its proprietary heat stabilization platform technology, ThermoVax®, in its vaccine development. The forward-looking statements in the release caution investors about risks and uncertainties, but the presentation of new data at prestigious dermatology conferences suggests growing momentum for HyBryte™ as a potential treatment option for CTCL patients who have limited therapeutic alternatives available to them.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Soligenix to Present HyBryte™ CTCL Trial Data at Dermatology Conference
